{ "labelLang" : "hun", "responseDate" : "2024-03-28 10:14", "content" : { "otype" : "JournalArticle", "mtid" : 31298911, "status" : "APPROVED", "published" : true, "comment" : "Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, NY, United States \n Department of Endocrinology, Diabetology & Metabolism, University of Antwerp–Antwerp University Hospital, Antwerp, Belgium \n Center for the Prevention of CVD, Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, NY, United States \n Cited By :39 \n Export Date: 20 July 2023 \n CODEN: JACCD \n Correspondence Address: Newman, J.D.; New York University School of Medicine, Translational Research Building, 227 East 30th, Suite 853, United States; email: jonathan.newman@nyumc.org \n Chemicals/CAS: albiglutide, 782500-75-8; alogliptin, 850649-61-5, 850649-62-6; biguanide, 56-03-1; chlorpropamide, 94-20-2; dulaglutide, 923950-08-7; exendin 4, 141732-76-5, 141758-74-9; glibenclamide, 10238-21-8; glimepiride, 93479-97-1; hemoglobin A1c, 62572-11-6; insulin, 9004-10-8; linagliptin, 668270-12-0; liraglutide, 204656-20-2; lixisenatide, 320367-13-3; metformin, 1115-70-4, 657-24-9; pioglitazone, 105355-27-9, 111025-46-8; saxagliptin, 361442-04-8, 945667-22-1; semaglutide, 910463-68-2; sitagliptin, 486460-32-6, 654671-78-0, 654671-77-9; Hypoglycemic Agents \n Funding details: \n Funding details: K23HL125991 \n Funding details: \n Funding details: \n Funding details: \n Funding details: \n Funding details: \n Funding text 1: Dr. De Block has received personal fees from AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lilly, Merck Sharp & Dohme, Novo Nordisk A/S, and Sanofi. Dr. Schwartzbard has received institutional support to NYU Langone Medical Center from Merck/Pfizer, Amarin, Sanofi, Novartis, and Amgen; and has served as an advisor to the formulary committee for Optum Rx. Dr. Newman has received grants from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) (K23HL K23HL125991); and has received honoraria from Creative Educational Concepts. Dr. Wilcox has reported that she has no relationships relevant to the contents of this paper to disclose. \n Funding text 2: Dr. De Block has received personal fees from AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lilly, Merck Sharp & Dohme, Novo Nordisk A/S, and Sanofi. Dr. Schwartzbard has received institutional support to NYU Langone Medical Center from Merck/Pfizer, Amarin, Sanofi, Novartis, and Amgen; and has served as an advisor to the formulary committee for Optum Rx. Dr. Newman has received grants from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) (K23HL K23HL125991); and has received honoraria from Creative Educational Concepts. Dr. Wilcox has reported that she has no relationships relevant to the contents of this paper to disclose.", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2024-03-20T15:14:30.419+0000", "lastModified" : "2023-03-14T09:00:34.753+0000", "created" : "2020-05-03T16:00:08.434+0000", "creator" : { "otype" : "Admin", "mtid" : 10071338, "link" : "/api/admin/10071338", "label" : "Molnár-Taga Márta (SE_AOK_1Bel_Onkol_Admin5_MTM, admin)", "familyName" : "Molnár-Taga", "givenName" : "Márta", "published" : true, "snippet" : true }, "lastDuplumOK" : "2024-03-18T12:05:01.826+0000", "lastDuplumSearch" : "2024-03-18T12:05:01.826+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Wilcox, T.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 91541039, "link" : "/api/authorship/91541039", "label" : "Wilcox, T.", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : false, "familyName" : "Wilcox", "givenName" : "T.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91541040, "link" : "/api/authorship/91541040", "label" : "De, Block C.", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "De", "givenName" : "Block C.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91541041, "link" : "/api/authorship/91541041", "label" : "Schwartzbard, A.Z.", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Schwartzbard", "givenName" : "A.Z.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 91541042, "link" : "/api/authorship/91541042", "label" : "Newman, J.D. ✉", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : true, "corresponding" : true, "familyName" : "Newman", "givenName" : "J.D.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 16879760, "link" : "/api/publicationidentifier/16879760", "label" : "DOI: 10.1016/j.jacc.2020.02.056", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1016/j.jacc.2020.02.056", "realUrl" : "https://doi.org/10.1016/j.jacc.2020.02.056", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16983375, "link" : "/api/publicationidentifier/16983375", "label" : "WoS: 000531872400013", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000531872400013", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000531872400013", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16879759, "link" : "/api/publicationidentifier/16879759", "label" : "Scopus: 85083791502", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85083791502", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85083791502", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 16983376, "link" : "/api/publicationidentifier/16983376", "label" : "PubMed: 32327107", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "32327107", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32327107&dopt=Abstract", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 2211, "link" : "/api/journal/2211", "label" : "JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597", "pIssn" : "0735-1097", "eIssn" : "1558-3597", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 2211, "snippet" : true }, "volume" : "75", "issue" : "16", "firstPage" : "1956", "lastPage" : "1974", "firstPageOrInternalIdForSort" : "1956", "pageLength" : 19, "publishedYear" : 2020, "digital" : true, "printed" : true, "sourceYear" : 2020, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2024-03-20", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 15, "citedCount" : 15, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10758712, "link" : "/api/sjrrating/10758712", "label" : "sjr:D1 (2020) Scopus - Cardiology and Cardiovascular Medicine JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597", "listPos" : 1, "rankValue" : 0.0, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2705, "link" : "/api/classificationexternal/2705", "label" : "Scopus - Cardiology and Cardiovascular Medicine", "published" : true, "oldId" : 2705, "snippet" : true }, "ranking" : "D1", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "D1", "referenceList" : "Di Angelantonio, E., Kaptoge, S., Wormser, D., Association of cardiometabolic multimorbidity with mortality (2015) JAMA, 314, pp. 52-60 ;\n Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy (2015) Lancet, 385, pp. 2107-2117 ;\n McMurray, J.J., Packer, M., Desai, A.S., Angiotensin–neprilysin inhibition versus enalapril in heart failure (2014) N Engl J Med, 371, pp. 993-1004 ;\n Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes (2008) N Engl J Med, 358, pp. 2560-2572 ;\n Effects of intensive glucose lowering in type 2 diabetes (2008) N Engl J Med, 358, pp. 2545-2559 ;\n DeFronzo, R.A., From the triumvirate to the “ominous octet”: a new paradigm for the treatment of type 2 diabetes mellitus (2009) Clini Diabetol, 10, pp. 101-128 ;\n Tahrani, A.A., Bailey, C.J., Del Prato, S., Barnett, A.H., Management of type 2 diabetes: new and future developments in treatment (2011) Lancet, 378, pp. 182-197 ;\n Cefalu, W.T., Kaul, S., Gerstein, H.C., Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum (2018) Diabetes Care, 41, pp. 14-31 ;\n Nathan, D.M., Buse, J.B., Davidson, M.B., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes (2009) Diabetes Care, 32, pp. 193-203 ;\n Inzucchi, S.E., Zinman, B., Fitchett, D., How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial (2018) Diabetes Care, 41, pp. 356-363 ;\n Davies, M.J., D'Alessio, D.A., Fradkin, J., Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018) Diabetes Care, 41, pp. 2669-2701 ;\n White, J.R., A brief history of the development of diabetes medications (2014) Diabetes Spectr, 27, pp. 82-86 ;\n Rena, G., Lang, C.C., Repurposing metformin for cardiovascular disease (2018) Circulation, 137, pp. 422-424 ;\n Group, U.P.D.S., Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) (1998) Lancet, 352, pp. 854-865 ;\n Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-Year follow-up of intensive glucose control in type 2 diabetes (2008) N Engl J Med, 359, pp. 1577-1589 ;\n Selvin, E., Bolen, S., Yeh, H.-C., Cardiovascular outcomes in trials of oral diabetes medications: a systematic review (2008) Arch Intern Med, 168, pp. 2070-2080 ;\n Lipska, K.J., Bailey, C.J., Inzucchi, S.E., Use of metformin in the setting of mild-to-moderate renal insufficiency (2011) Diabetes Care, 34, pp. 1431-1437 ;\n Inzucchi, S.E., Lipska, K.J., Mayo, H., Bailey, C.J., McGuire, D.K., Metformin in patients with type 2 diabetes and kidney disease: a systematic review (2014) JAMA, 312, pp. 2668-2675 ;\n Bergmark, B.A., Bhatt, D.L., McGuire, D.K., Metformin use and clinical outcomes among patients with diabetes with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial (2019) Circulation, 140, pp. 1004-1014 ;\n Lalau, J.-D., Kajbaf, F., Bennis, Y., Hurtel-Lemaire, A.-S., Belpaire, F., De Broe, M.E., Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4 (2018) Diabetes Care, 41, pp. 547-553 ;\n Cosentino, F., Grant, P.J., Aboyans, V., 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) (2020) Eur Heart J, 41, pp. 255-323 ;\n Sigal, R.J., El-Hashimy, M., Martin, B.C., Soeldner, J.S., Krolewski, A.S., Warram, J.H., Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study (1997) Diabetes, 46, pp. 1025-1029 ;\n Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J.E., Gerstein, H.C., The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis (2010) Diabetes Care, 33, pp. 1859-1864 ;\n Wright, A., Burden, A.F., Paisey, R.B., Cull, C.A., Holman, R.R., Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57) (2002) Diabetes Care, 25, pp. 330-336 ;\n Meinert, C.L., Knatterud, G.L., Prout, T.E., Klimt, C.R., A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results (1970) Diabetes, 19, pp. 789-830 ;\n Rados, D.V., Pinto, L.C., Remonti, L.R., Leitão, C.B., Gross, J.L., The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials (2016) PLoS Med, 13 ;\n Rosenstock, J., Kahn, S.E., Johansen, O.E., Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial (2019) JAMA, 322, pp. 1155-1166 ;\n Association, A.D., Standards of medical care in diabetes—2016 abridged for primary care providers (2016) Clin Diabetes, 34, p. 3 ;\n Tseng, C.-L., Soroka, O., Maney, M., Aron, D.C., Pogach, L.M., Assessing potential glycemic overtreatment in persons at hypoglycemic risk (2014) JAMA Intern Med, 174, pp. 259-268 ;\n Yki-Jarvinen, H., Thiazolidinediones (2004) N Engl J Med, 351, pp. 1106-1118 ;\n Lathief, S., Inzucchi, S.E., Approach to diabetes management in patients with CVD (2016) Trends Cardiovasc Med, 26, pp. 165-179 ;\n Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial (2005) Lancet, 366, pp. 1279-1289 ;\n Home, P.D., Pocock, S.J., Beck-Nielsen, H., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009) Lancet, 373, pp. 2125-2135 ;\n Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (2007) N Engl J Med, 356, pp. 2457-2471 ;\n Schneider, C.A., Ferrannini, E., DeFronzo, R., Schernthaner, G., Yates, J., Erdmann, E., Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease (2008) J Am Soc Nephrol, 19, pp. 182-187 ;\n Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action (2013) Cell Metab, 17, pp. 819-837 ;\n Scheen, A.J., Cardiovascular effects of gliptins (2013) Nat Rev Cardiol, 10, p. 73 ;\n Bloomgarden, Z., The kidney and cardiovascular outcome trials (2018) J Diabetes, 10, pp. 88-89 ;\n Green, J.B., Bethel, M.A., Armstrong, P.W., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes (2015) N Engl J Med, 373, pp. 232-242 ;\n McGuire, D., Van de Werf, F., Armstrong, P., Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) study group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial (2016) JAMA Cardiol, 1, pp. 126-135 ;\n Scirica, B.M., Bhatt, D.L., Braunwald, E., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (2013) N Engl J Med, 369, pp. 1317-1326 ;\n Zannad, F., Cannon, C.P., Cushman, W.C., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial (2015) Lancet, 385, pp. 2067-2076 ;\n White, W.B., Cannon, C.P., Heller, S.R., Alogliptin after acute coronary syndrome in patients with type 2 diabetes (2013) N Engl J Med, 369, pp. 1327-1335 ;\n Rosenstock, J., Perkovic, V., Johansen, O.E., Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial (2019) JAMA, 321, pp. 69-79 ;\n Ingelheim, B., CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine https://clinicaltrials/.gov/show/NCT01243424, Available at: Accessed December 20, 2019 ;\n FDA Drug Safety Communication https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes, Available at: Accessed December 20, 2019 ;\n Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J., Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? (2011) Diabetologia, 54, pp. 10-18 ;\n Drucker, D.J., The biology of incretin hormones (2006) Cell Metab, 3, pp. 153-165 ;\n Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (2006) Lancet, 368, pp. 1696-1705 ;\n Pi-Sunyer, X., Astrup, A., Fujioka, K., A randomized, controlled trial of 3.0 mg of liraglutide in weight management (2015) N Engl J Med, 373, pp. 11-22 ;\n Muskiet, M.H., Tonneijck, L., Smits, M.M., GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes (2017) Nat Rev Nephrol, 13, p. 605 ;\n Madsbad, S., Holst, J.J., Treatment with GLP-1 receptor agonists (2018) Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, pp. 1-45. , E. Bonora R. DeFronzo Springer International Publishing Cham, Germany ;\n Holman, R.R., Bethel, M.A., Mentz, R.J., Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (2017) N Engl J Med, 377, pp. 1228-1239 ;\n Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Liraglutide and cardiovascular outcomes in type 2 diabetes (2016) N Engl J Med, 375, pp. 311-322 ;\n Marso, S.P., Bain, S.C., Consoli, A., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (2016) N Engl J Med, 375, pp. 1834-1844 ;\n Pfeffer, M.A., Claggett, B., Diaz, R., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (2015) N Engl J Med, 373, pp. 2247-2257 ;\n Hernandez, A.F., Green, J.B., Janmohamed, S., Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) Lancet, 392, pp. 1519-1529 ;\n Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (2019) Lancet, 394, pp. 121-130 ;\n Husain, M., Birkenfeld, A.L., Donsmark, M., Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (2019) N Engl J Med, 381, pp. 841-851 ;\n FDA Approves CVD Benefit for Once-Weekly Semaglutide https://www.medscape.com/viewarticle/923922, Available at: Accessed December 20, 2019 ;\n A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL) https://clinicaltrials.gov/ct2/show/NCT03914326, Available at: Accessed December 20, 2019 ;\n Newman, J.D., Vani, A.K., Aleman, J.O., Weintraub, H.S., Berger, J.S., Schwartzbard, A.Z., The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC State-of-the-Art Review (2018) J Am Coll Cardiol, 72, pp. 1856-1869 ;\n Kristensen, S.L., Rorth, R., Jhund, P.S., Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) Lancet Diabetes Endocrinol, 7, pp. 776-785 ;\n Tuttle, K.R., Lakshmanan, M.C., Rayner, B., Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial (2018) Lancet Diabetes Endocrinol, 6, pp. 605-617 ;\n Vilsboll, T., Bain, S.C., Leiter, L.A., Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy (2018) Diabetes Obes Metab, 20, pp. 889-897 ;\n Monami, M., Dicembrini, I., Mannucci, E., Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials (2017) Acta Diabetol, 54, pp. 19-36 ;\n Margulies, K.B., Hernandez, A.F., Redfield, M.M., Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial (2016) JAMA, 316, pp. 500-508 ;\n Gerich, J.E., Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications (2010) Diabetes Med, 27, pp. 136-142 ;\n Rieg, T., Vallon, V., Development of SGLT1 and SGLT2 inhibitors (2018) Diabetologia, 61, pp. 2079-2086 ;\n Chasis, H., Jolliffe, N., Smith, H.W., The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man (1933) J Clin Invest, 12, pp. 1083-1090 ;\n Kanai, Y., Lee, W.S., You, G., Brown, D., Hediger, M.A., The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose (1994) J Clin Invest, 93, pp. 397-404 ;\n Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside (2015) Diabetes Care, 38, pp. 2344-2353 ;\n Santer, R., Calado, J., Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target (2010) Clin J Am Soc Nephrol, 5, pp. 133-141 ;\n Gallo, L.A., Wright, E.M., Vallon, V., Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences (2015) Diabetes Vasc Dis Res, 12, pp. 78-89 ;\n Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes (2005) Diabetes, 54, pp. 3427-3434 ;\n Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications (2016) Circulation, 134, pp. 752-772 ;\n Borghi, C., Rosei, E.A., Bardin, T., Serum uric acid and the risk of cardiovascular and renal disease (2015) J Hypertens, 33, pp. 1729-1741 ;\n Zinman, B., Wanner, C., Lachin, J.M., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (2015) N Engl J Med, 373, pp. 2117-2128 ;\n Carson, J.L., Brooks, M.M., Abbott, J.D., Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease (2013) Am Heart J, 165, pp. 964-971 ;\n Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys (2016) J Clin Med Res, 8, p. 844 ;\n Ferrannini, G., Rydén, L., Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data (2018) Clin Sci, 132, pp. 2003-2012 ;\n Lytvyn, Y., Bjornstad, P., Udell, J.A., Lovshin, J.A., Cherney, D.Z., Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials (2017) Circulation, 136, pp. 1643-1658 ;\n Scheen, A.J., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors (2018) Circ Res, 122, pp. 1439-1459 ;\n Packer, M., Anker, S.D., Butler, J., Filippatos, G., Zannad, F., Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action (2017) JAMA Cardiol, 2, pp. 1025-1029 ;\n Heerspink, H.J., Kosiborod, M., Inzucchi, S.E., Cherney, D.Z., Renoprotective effects of sodium-glucose cotransporter-2 inhibitors (2018) Kidney Int, 94, pp. 26-39 ;\n Neal, B., Perkovic, V., Mahaffey, K.W., Canagliflozin and cardiovascular and renal events in type 2 diabetes (2017) N Engl J Med, 377, pp. 644-657 ;\n Wiviott, S.D., Raz, I., Bonaca, M.P., Dapagliflozin and cardiovascular outcomes in type 2 diabetes (2018) N Engl J Med, 380, pp. 347-357 ;\n Perkovic, V., Jardine, M.J., Neal, B., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) N Engl J Med, 380, pp. 2295-2306 ;\n Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging https://clinicaltrials.gov/ct2/results?cond=&term=NCT00729430&cntry=&state=&city=&dist=, Available at: Accessed December 20, 2019 ;\n Wanner, C., Inzucchi, S.E., Lachin, J.M., Empagliflozin and progression of kidney disease in type 2 diabetes (2016) N Engl J Med, 375, pp. 323-334 ;\n Zelniker, T.A., Wiviott, S.D., Raz, I., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2019) Lancet, 393, pp. 31-39 ;\n (2019), http://med.stanford.edu/content/dam/sm/sccr/documents/June%202019ADA%202019_CREDENCE%20symposium_FINAL%20for%20posting.pdf, CREDENCE: Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation. Available at: Accessed December 20 ;\n Udell, J.A., Yuan, Z., Rush, T., Sicignano, N.M., Galitz, M., Rosenthal, N., Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World) (2018) Circulation, 137, pp. 1450-1459 ;\n Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors (2015) Diabetes Care, 38, pp. 1638-1642 ;\n Levine, R., Sulfonylureas: background and development of the field (1984) Diabetes Care, 7, pp. 3-7 ;\n Hulin, B., McCarthy, P.A., Gibbs, E.M., The glitazone family of antidiabetic agents (1996) Curr Pharm Des, 2, pp. 85-102 ;\n Sebokova, E., Christ, A.D., Boehringer, M., Mizrahi, J., Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes (2007) Curr Top Med Chem, 7, pp. 547-555 ;\n Ehrenkranz, J.R., Lewis, N.G., Ronald Kahn, C., Roth, J., Phlorizin: a review (2005) Diabetes Metab Res Rev, 21, pp. 31-38 ;\n 1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes—2018 (2018) Diabetes Care, 41, pp. S7-S12 ;\n 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020 (2020) Diabetes Care, 43, pp. S98-S110 ;\n McMurray, J.J., Solomon, S.D., Inzucchi, S.E., Dapagliflozin in patients with heart failure and reduced ejection fraction (2019) N Engl J Med, 381, pp. 1995-2008 ;\n Drucker, D.J., Habener, J.F., Hoist, J.J., Discovery, characterization, and clinical development of the glucagon-like peptides (2017) J Clin Invest, 127, pp. 4217-4227", "hasCitationDuplums" : false, "userChangeableUntil" : "2020-08-17T13:00:49.559+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 40, "ownerInstituteCount" : 101, "directInstituteCount" : 0, "authorCount" : 4, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/31298911", "label" : "Wilcox T. et al. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. (2020) JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 1558-3597 75 16 1956-1974", "template" : "